ResearcherStony Brook UniversityActive in the last 2 years
Lucia Roa‐Peña
Matched on ORCID iD 0000-0002-3037-4906; OpenAlex author ID A5023282465. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 19
2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper
Papers 8
- Mitochondrial-Localized Keratin 17 Promotes Chemoresistance in Basal-like Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-4534↗
- Advancing Precision Medicine in PDAC: An Ethical Scoping Review and Call to Action for IHC Implementation. First author DOI 10.3390/cancers17121899↗
- Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. First author DOI 10.1093/ajcp/aqae038↗
- Keratin 17 modulates the immune topography of pancreatic cancer. Co-author DOI 10.1186/s12967-024-05252-1↗
- Targeting keratin 17-mediated reprogramming of de novo pyrimidine biosynthesis to overcome chemoresistance in pancreatic cancer Co-author DOI 10.1101/2022.08.24.504873↗
- Disassembly of embryonic keratin filaments promotes pancreatic cancer metastases Co-author DOI 10.1101/2022.08.27.504988↗
- Keratin 17 testing in pancreatic cancer needle aspiration biopsies predicts survival. Co-author DOI 10.1002/cncy.22438↗
- Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer. Co-author DOI 10.1038/s41598-019-47519-4↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Luisa F. Escobar‐Hoyos · 8 shared papers, 2019–2026 · strength 1.37
- Paper Advancing Precision Medicine in PDAC: An Ethical Scoping Review and Call to Action for IHC Implementation. DOI 10.3390/cancers17121899↗
- Paper Mitochondrial-Localized Keratin 17 Promotes Chemoresistance in Basal-like Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-4534↗
- Paper Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. DOI 10.1093/ajcp/aqae038↗
- Kenneth Reed Shroyer · 8 shared papers, 2019–2026 · strength 1.37
- Paper Advancing Precision Medicine in PDAC: An Ethical Scoping Review and Call to Action for IHC Implementation. DOI 10.3390/cancers17121899↗
- Paper Mitochondrial-Localized Keratin 17 Promotes Chemoresistance in Basal-like Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-4534↗
- Paper Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. DOI 10.1093/ajcp/aqae038↗
- Lyanne Delgado Coka · 4 shared papers, 2024–2026 · strength 0.87
- Paper Advancing Precision Medicine in PDAC: An Ethical Scoping Review and Call to Action for IHC Implementation. DOI 10.3390/cancers17121899↗
- Paper Mitochondrial-Localized Keratin 17 Promotes Chemoresistance in Basal-like Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-4534↗
- Paper Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. DOI 10.1093/ajcp/aqae038↗
- Chun‐Hao Pan · 4 shared papers, 2019–2026 · strength 0.58
- Paper Mitochondrial-Localized Keratin 17 Promotes Chemoresistance in Basal-like Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-4534↗
- Paper Disassembly of embryonic keratin filaments promotes pancreatic cancer metastases DOI 10.1101/2022.08.27.504988↗
- Paper Targeting keratin 17-mediated reprogramming of de novo pyrimidine biosynthesis to overcome chemoresistance in pancreati… DOI 10.1101/2022.08.24.504873↗
- Nina V. Chaika · 2 shared papers, 2022–2026 · strength 0.34
- Pankaj Kumar Singh · 2 shared papers, 2022–2026 · strength 0.34
- Emanuel F. Petricoin · 2 shared papers, 2024 · strength 0.33
- Andrew Eugene Hendifar · 2 shared papers, 2024 · strength 0.33
- Brent K. Larson · 2 shared papers, 2024 · strength 0.33
- Wei Jiang · 2 shared papers, 2024 · strength 0.33
- Lynn McCormick Matrisian · 2 shared papers, 2024 · strength 0.33
- Shayan Sarkar · 1 shared paper, 2026 · strength 0.21
- David Arthur Tuveson · 1 shared paper, 2026 · strength 0.21
- Minsig Choi · 1 shared paper, 2024 · strength 0.17
- Vincent J. Picozzi · 1 shared paper, 2024 · strength 0.17
- Ryan R. Kawalerski · 1 shared paper, 2022 · strength 0.14
- Luke A. Torre-Healy · 1 shared paper, 2022 · strength 0.14
- Jonathan M. Buscaglia · 1 shared paper, 2021 · strength 0.13
- Richard A. Moffitt · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.